Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024.
- Additionally, clinical data from the previously completed investigator-initiated trial in patients with ALS is also anticipated in the second quarter.
- 2 investigator-initiated trial involving COYA 301, or low-dose IL-2 alone, is expected in the summer of 2024.
- As of March 31, 2024, Coya had cash and cash equivalents of $36.0 million.